The Pseudomonas Aeruginosa Infection Treatment Market is expected to register a CAGR of nearly 4.7% during the forecast period.
Pseudomonas Aeruginosa is a common encapsulated, Gram-negative, rod-shaped bacterium that can cause disease in humans. P. aeruginosa is a multidrug-resistant pathogen recognized for its ubiquity, its intrinsically advanced antibiotic resistance mechanisms, and its association with serious illnesses including hospital-acquired infections such as ventilator-associated pneumonia and various sepsis syndromes.
The ongoing outbreak of the COVID-19 pandemic impacted the pharmaceutical industry positively. It affects the pseudomonas aeruginosa treatment market. Recently, “oral ciprofloxacin” drug products are used to treat p. auregeniosa infected patients with COVID-19 Pneumonia in Patients with COVID-19. The expanded therapy for P aeruginosa and methicillin-resistant S aureus reduces antibiotic use in patients. “America Thoracic Society and Infection Disease” provide a guideline for the treatment of adults with community-acquired pneumonia and COVID-19. These factors propel the growth of the market.
The major factors such as the growing patient population infected with pseudomonas aeruginosa infection, increasing incidence of infections associated with pseudomonas aeruginosa such as pneumonia, cystic fibrosis, urinary tract infections increasing development of products, increasing antibacterial resistance, and growing R&D activities are driving the growth of pseudomonas aeruginosa infection market.
The prevalence of Hospital Acquired Infections has increased in recent years. According to an article titled ‘Community-Acquired Pneumonia’ published in August 2021, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases. This has led to an increase in research and development in understanding P. aeruginosa. As a result, many drugs are in pipeline for the treatment of this infection. These factors have helped the growth of the market and are expected to help in the future as well.
However, as stated earlier, P. aeruginosa shows the ability of drug resistance. As a result, many drug developers, who have limited funds are dissuaded from the market. This factor has been hindering the market growth.
Key Market Trends
Combination Therapy is expected to Dominate the Market
Combination therapy for the treatment of P. aeruginosa is administered due to different considerations. First, to cover the known or suspected pathogen while results of identification and susceptibility testing are pending, second, to avoid the emergence of resistance during treatment, and third, due to possible synergistic activity resulting in better clinical outcome.
According to an article titled ‘Effect of Imipenem and Amikacin Combination against Multi-Drug Resistant Pseudomonas aeruginosa’ published in November 2021, antimicrobial susceptibility testing showed that P. aeruginosa strains were highly resistant to ceftazidime (88.9%) and cefepime (82.2%) which was most prevalent among wound infections. Imipenem and amikacin were the most effective drug with the least resistance percentage (28.9%). The research concluded that the drug combination viewed a statistically significant reduction in bacterial counts, receiving definite combination therapy, as compared to monotherapy and combination therapy showed good results.
Due to the benefits of combination therapy over monotherapy, this market is expected to increase in the forecast period.
North America is Expected to Dominate the Market
As per a report by the Agency for Healthcare Research and Quality, 2019, approximately 1 of every 25 hospitalized patients in the United States have a hospital-acquired infection (HAI). This ratio translated to nearly 650,000 patients contracting one of these infections annually. According to the American Association for the Advancement of Science, the proportion of patients with a hospital-acquired infection was 7.9% in 2017, in Canadian Hospitals. As Pseudomonas aeruginosa infection is common, the probability of this infection is still prevalent in these countries.
According to an article titled ‘Community-Acquired Pneumonia’ published in August 2021, The annual incidence in the United States is 24.8 cases per 10,000 adults, with higher rates as people get older. Pneumonia is the eighth most common cause of mortality and the top among infectious diseases. Patients hospitalized in the intensive care unit have a death rate of up to 23%. Additionally, as per the publication in Biomedical and Pharmacology journal 2021, women under 19 years affected with COVID-19 also developed pneumonia. The nationwide prevalence of pneumonia was 2.81 percent, with the highest prevalence of 13.77 percent in Veracruz, followed by 12.66 percent in Nayarit 12.08 percent in Quintana Roo, and 0.71 percent in Durango. The attributable fractions and odds ratios were estimated using Durango as the baseline group. As the increasing prevalence of infections related to the respiratory tract is expected to create more demand for Pseudomonas Aeruginosa infection treatment market in the North American region.
However, the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. As high and increasing demand is met by the presence of global players in the region, the market is further expected to increase.
Majority of the Pseudomonas Aeruginosa Infection Treatment drugs and therapies are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing an emergence of some small players due to the rise of awareness. This has also helped the market grow.
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.2 Study Assumptions
1.3 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Prevalence of Hospital Acquired Infections
4.2.2 Investment in Research and Drug Discovery for Pseudomonas Aeruginosa
4.3 Market Restraints
4.3.1 Drug Resistance Ability of Pseudomonas Aeruginosa
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.2 Combination Therapy
5.2 By Route of Administration
5.3.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 South Korea
126.96.36.199 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
188.8.131.52 South Africa
184.108.40.206 Rest of Middle-East and Africa
5.3.5 South America
220.127.116.11 Rest of South America
6.1.1 AbbVie Inc. (Allergan plc)
6.1.2 Teva Pharmaceutical Industries Ltd.
6.1.3 Pfizer, Inc.
6.1.4 Lupin Pharmaceuticals, Inc.
6.1.5 AstraZeneca plc
6.1.6 Merck & Co., Inc.
6.1.7 Bristol Myers Squibb Company
6.1.8 Johnson & Johnson
A selection of companies mentioned in this report includes:
- AbbVie Inc. (Allergan plc)
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- Lupin Pharmaceuticals, Inc.
- AstraZeneca plc
- Merck & Co., Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson